

10/536613

Report PCT/PTO 25 MAY 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**CORRECTED VERSION**

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number  
**WO 2004/048340 A1**

(51) International Patent Classification<sup>7</sup>: C07D 221/28,  
489/00, A61K 31/485

Room 1208, N°2, Lane 69, Tian-Yue-Qiao Road, 200030  
Shanghai, People's Republic of China (CN). LESTAGE,  
Pierre [FR/FR]; 9 Allée de la Grande Terre, F-78170  
La Celle Saint Cloud (FR). CAIGNARD, Daniel-Henri  
[FR/FR]; 22, avenue de la République, F-78203 Le Pecq  
(FR). RENARD, Pierre [FR/FR]; 3, avenue du Parc,  
F-78150 Le Chesnay (FR).

(21) International Application Number:  
PCT/EP2003/014841

(22) International Filing Date:  
26 November 2003 (26.11.2003)

(74) Common Representative: LES LABORATOIRES  
SERVIER; 12, Place de la Défense, F-92415 Courbevoie  
Cédex (FR).

(25) Filing Language: English  
(26) Publication Language: English  
(30) Priority Data:  
02 1 53819.0 28 November 2002 (28.11.2002) CN

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,  
CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,  
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,  
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,  
SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicants (for all designated States except US):  
SHANGHAI INSTITUTE OF MATERIA MEDICA,  
CHINESE ACADEMY OF SCIENCES [CN/CN]; Zu  
chong-zhi Road 555, Zhangjiang Hi-Tech Park, Pudong,  
Shanghai, People's Republic of China (CN). LES LABO-  
RATOIRES SERVIER [FR/FR]; 12, Place de la Défense,  
F-92415 Courbevoie Cédex (FR).

(84) Designated States (regional): ARIPO patent (BW, GH,  
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,  
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


Published:

(75) Inventors/Applicants (for US only): QIN, Guo-Wei  
[CN/CN]; Room 907, No. 1, Lane 69, Tian-Yue-Qiao  
Road, 200030 Shanghai, People's Republic of China  
(CN). TANG, Xi-Can [CN/CN]; Room 609, No.800,  
Cao-Xi-Bei Road, 200030 Shanghai, People's Republic of  
China (CN). WANG, Rui [CN/CN]; Room 501, N°1, Lane  
1717, Xi-Zang-Nan Road, 200030 Shanghai, People's  
Republic of China (CN). ZHOU, Tian-Xi [CN/CN];


— with international search report

[Continued on next page]


(54) Title: SINOMENINE AND SINOMENINE COMPOUNDS, SYNTHESIS AND USE



(57) Abstract: The invention relates to sinomenine and compounds thereof and also to compounds of formula (I), wherein R<sub>1</sub> represents an alkyl group; R<sub>2</sub> represents a hydrogen atom or an alkylcarbonyl group, an haloalkylcarbonyl group or an arylcarbonyl; Y represents a group (II), (III) or (IV); R<sub>3</sub>, R<sub>4</sub>, R'<sub>4</sub>, R<sub>5</sub>, R'<sub>5</sub> and R<sub>6</sub> are as defined in the description; and X represents a halogen atom. Medicaments.



(III)



WO 2004/048340 A1

105536613

Rec'd PCT/PTO 25 MAY 2005  
PATENT COOPERATION TREATY (PCT)

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

**(19) World Intellectual Property Organization  
International Bureau**



**(43) International Publication Date  
10 June 2004 (10.06.2004)**

PCT

(10) International Publication Number  
**WO 2004/048340 A1**

- (51) International Patent Classification<sup>7</sup>: C07D 221/28,  
489/00, A61K 31/485

(21) International Application Number:  
PCT/EP2003/014841

(22) International Filing Date:  
26 November 2003 (26.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02 1 53819.0 28 November 2002 (28.11.2002) CN

(71) Applicant (for all designated States except US): SHANGAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES [CN/CN]; Zu chong-zhi Road 555, Zhangjiang Hi-Tech Park, Pudong, Shanghai, People's Republic of China (CN).

(71) Applicant (for US only): LES LABORATOIRES SERVIER [FR/FR]; 12, Place de la Défense, F-92415 Courbevoie Cedex (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): QIN, Guo-Wei [CN/CN]; Room 907, No. 1, Lane 69, Tian-Yue-Qiao Road, 200030 Shanghai, People's Republic of China (CN). TANG, Xi-Can [CN/CN]; Room 609, No.800, Cao-Xi-Bei Road, 200030 Shanghai, People's Republic of China (CN). WANG, Rui [CN/CN]; Room 501, N°1, Lane 1717, Xi-Zang-Nan Road, 200030 Shanghai, People's Republic of China (CN). ZHOU, Tian-Xi [CN/CN]; Room 1208, N°2, Lane 69, Tian-Yue-Qiao Road, 200030 Shanghai, People's Republic of China (CN). LESTAGE, Pierre [FR/FR]; 9 Allée de la Grande Terre, F-78170 La Celle Saint Cloud (FR). CAIGNARD, Daniel-Henri [FR/FR]; 22, avenue de la République, F-78203 Le Pecq (FR). RENARD, Pierre [FR/FR]; 3, avenue du Parc, F-78150 Le Chesnay (FR).

(74) Common Representative: LES LABORATOIRES SERVIER; 12, Place de la Défense, F-92415 Courbevoie Cedex (FR).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


**Published:**  
— with international search report

**Published:**

— with international search report

[Continued on next page]

**(54) Title: SINOMENINE AND SINOMENINE COMPOUNDS, SYNTHESIS AND USE**



**(57) Abstract:** The invention relates to sinomenine and compounds thereof and also to compounds of formula (I), wherein R<sub>1</sub> represents an alkyl group; R<sub>2</sub> represents a hydrogen atom or an alkylcarbonyl group, an haloalkylcarbonyl group or an arylcarbonyl; Y represents a group (II), (III) or (IV); R<sub>3</sub>, R<sub>4</sub>, R'4, R<sub>5</sub>, R'5 and R<sub>6</sub> are as defined in the description; and X represents a halogen atom. Medicaments.

WO 2004/048340 A1



*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## SINOMENINE AND SINOMENINE COMPOUNDS, SYNTHESIS AND USE

*Sinomenium acutum* is a plant taking the form of a ligneous liana, which is widespread in the centre, South-East and South-West of China and is included in the Chinese Pharmacopoeia (Pharmacopoeia Committee of People's Republic of China, 2000). It contains a large number of alkaloids of various chemical structures, such as sinomenine, sinoacutine, ethylsinomenine, disinomenine, tetrahydroepiberberine, tuduranine and magnoflorine (Huang Tai-Kang, « *Handbook of the Composition and Pharmacology of Common Chinese Drugs* », Chinese Medical Science and Technology Publisher, 1994, Beijing, 1156-1160).

Sinomenine, a morphine-like alkaloid and a major constituent of the plant, has been much studied; in particular, it has been possible to demonstrate anti-inflammatory, immunosuppressive, anti-arrhythmic and analgesic properties (Qiang Liu *et al.*, Chinese Traditional and Herbal Drugs, 1997, 28(4), 247).


We have now discovered that sinomenine has mnemocognition-facilitating properties in animal experimental models.

Ageing of the population due to increased life expectancy has brought with it a major increase in cognitive disorders associated with normal cerebral ageing or pathological cerebral ageing occurring in the course of neurodegenerative diseases such as, for example, Alzheimer's disease.

The majority of substances used today in treating cognitive disorders associated with ageing act by facilitating the central cholinergic systems – either directly, as in the case of acetylcholinesterase inhibitors (tacrine, donepezil) and cholinergic agonists (nefiracetam), or indirectly, as in the case of nootropic agents (piracetam, pramiracetam) and cerebral vasodilators (vincamine).


It has therefore been especially valuable to synthesise new compounds that are capable of opposing the cognitive disorders associated with ageing and/or of improving cognitive processes.

The present invention relates, on the one hand, to the use of sinomenine :



and/or sinomenine compounds in mnemocognitive disorders and, on the other hand, to the synthesis of new compounds having especially valuable pharmacological properties in the  
5 same area.

The present invention relates more specifically to compounds of formula (I) :



wherein

- R<sub>1</sub> represents an alkyl group,
- R<sub>2</sub> represents a hydrogen atom or an alkylcarbonyl group, an haloalkylcarbonyl group or an arylcarbonyl group,
- Y represents a group  $\begin{array}{c} \diagup \\ \diagdown \end{array} NR_7$ ,  $\begin{array}{c} + \\ | \\ O^- \\ | \\ R_7 \end{array}$  or  $\begin{array}{c} + \\ | \\ N(R_7)R'_7 \\ | \\ Z^- \end{array}$

wherein R<sub>7</sub> and R'<sub>7</sub>, identical or different, each represent an alkyl group, and Z<sup>-</sup> represents a halogen anion,

- R<sub>3</sub> represents a hydroxy or alkoxy group,
- R<sub>4</sub> and R'<sub>4</sub> each represent a hydrogen atom or together form an additional bond, or R<sub>3</sub> and R<sub>4</sub> together form an oxo or =N-OR<sub>8</sub> group (wherein R<sub>8</sub> represents a hydrogen atom or an alkyl group),

- R<sub>6</sub> represents a hydroxy, alkylcarbonyloxy (wherein the alkyl moiety can be substituted by a hydroxy, alkoxy, carboxy or alkyloxycarbonyl group) or alkoxy group,
- R<sub>5</sub> and R'<sub>5</sub> each represent a hydrogen atom or together form an additional bond, or R<sub>5</sub> and R<sub>6</sub> together form an oxo, =N-OR<sub>9</sub> or =N-NR<sub>10</sub>R<sub>11</sub> group (wherein R<sub>9</sub>, R<sub>10</sub>, and R<sub>11</sub>, which may be the same or different, each represent a hydrogen atom or an alkyl group),
- and X represents a halogen atom,

with the proviso that the compound of formula (I) cannot represent 1-bromo-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one,  
10

it being understood that


- "alkyl" means an alkyl group containing 1 to 6 carbon atoms which may be linear or branched,
- "alkoxy" means an alkyloxy group containing 1 to 6 carbon atoms which may be linear or branched,

15 to their enantiomers and diastereoisomers, and to addition salts thereof with a pharmaceutically acceptable acid or base.

Among the pharmaceutically acceptable acids there may be mentioned, without implying any limitation, hydrochloric acid, hydrobromic acid, sulphuric acid, phosphonic acid, acetic acid, trifluoroacetic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, methanesulphonic acid, camphoric acid, oxalic acid etc..  
20

Among the pharmaceutically acceptable bases there may be mentioned, without implying any limitation, sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine etc..

25 The preferred configuration of compounds of formula (I) according to the invention is that shown in formula (I'):



The preferred group  $R_1$  is the methyl group.

Advantageously,  $R_2$  represents a hydrogen atom or a group  $\text{EtCO}$  and more preferably a hydrogen atom.

$Y$  represents, preferably, a group  $\text{NR}_7$  or  $\begin{array}{c} + \\ \diagup \\ \text{N} \\ \diagdown \\ \text{R}_7 \end{array} \text{O}^-$  and, more especially, a group  $\begin{array}{c} + \\ \diagup \\ \text{N} \\ \diagdown \\ \text{Me} \end{array} \text{Me}$  or  $\begin{array}{c} + \\ \diagup \\ \text{N} \\ \diagdown \\ \text{Me} \end{array} \text{O}^-$ .

$X$  represents, very preferably, a chlorine or bromine atom.


5 Advantageously, the invention relates to compounds of formula (I) wherein  $R_3$  represents an alkoxy group and  $R_4$  and  $R'_4$  together form an additional bond.

The preferred meaning of  $R_5$  is a hydrogen atom.

10  $R_6$  represents advantageously an OH, ethoxy or alkylcarbonyloxy group and, more especially, ethylcarbonyloxy.

Another interesting aspect of the invention is compounds of formula (I) for which  $R_5$  and  $R_6$  form together an oxo group or an  $=\text{N}-\text{OH}$  group.

Very preferably, the invention relates to compounds of formula (I'') and (I''') :



wherein Y' represents  $\text{N}-\text{Me}$  or  $\text{N}^+\text{Me}^-\text{O}^-$ , R'<sub>2</sub> and R'<sub>6</sub>, which may be the same or different, represent a hydrogen atom or an alkylcarbonyl group, X' represents a chlorine or bromine atom and Z represents  $=\text{O}$  or  $=\text{N}-\text{OH}$ .

Even more preferably, the invention relates to compounds of formula (I) that are (9 $\alpha$ ,13 $\alpha$ )-1-chloro-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-4,6-diol, (9 $\alpha$ ,13 $\alpha$ )-1-chloro-3,7-dimethoxy-17-methyl-4-(propionyloxy)-7,8-didehydromorphinan-6-yl propionate, (9 $\alpha$ ,13 $\alpha$ )-1-bromo-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-4,6-diol, (9 $\alpha$ ,13 $\alpha$ )-1-bromo-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one oxime, (9 $\alpha$ ,13 $\alpha$ )-1-bromo-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one N-oxide, (9 $\alpha$ ,13 $\alpha$ )-1-chloro-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one N-oxide.


5

The enantiomers and diastereoisomers and addition salts with a pharmaceutically acceptable acid or base of the preferred compounds of the invention form an integral part of the invention.

10


The invention relates also to a process for the preparation of compounds of formula (I), which process is characterised in that there is used as starting material the compound of formula (II) :

15




20

obtained by extraction starting from the stem of *Sinomenium acutum* according to Figure 1 below :



**Figure 1 : Extraction of the compound of formula (II)**

which is subjected to the action of a halogenating agent such as  $\text{SO}_2\text{Cl}_2$  or  $\text{Br}_2$  to obtain the compound of formula (I/a), a particular case of the compounds of formula (I):



wherein X is as defined for formula (I), which compound of formula (I/a) is subjected to conventional chemical reactions to obtain the totality of the compounds of formula (I), which may be purified according to a conventional separation technique, are converted, if desired, into their addition salts with a pharmaceutically acceptable acid or base and are separated, where appropriate, into their isomers according to a conventional separation technique.

10 Besides the fact that the compounds of the present invention are new, they possess properties of facilitating cognitive processes, making them of use in the treatment of cognitive deficiencies associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias.


15 The invention relates also to pharmaceutical compositions comprising as active ingredient at least one compound of formula (I) together with one or more appropriate, inert, non-toxic excipients.

The Applicant has moreover discovered that sinomenine and/or sinomenine compounds have mnemocognition-facilitating properties.

20 The invention accordingly relates also to the use of sinomenine and/or sinomenine compounds in obtaining pharmaceutical compositions for use in the treatment of cognitive

deficiencies associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias.

More especially, the invention relates to the use, in obtaining pharmaceutical compositions for use in the treatment of cognitive deficiencies associated with cerebral ageing and with neurodegenerative diseases, of sinomenine and/or sinomenine compounds such as, for example, the compounds of formula (Ia) :



wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R'<sub>4</sub>, R<sub>5</sub>, R'<sub>5</sub>, R<sub>6</sub> and Y are as defined for formula (I), and, more especially, of (9α,13α)-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one hydrazone; (7α,9α,13α)-4-hydroxy-3,7-dimethoxy-17-methylmorphinan-6-one; (7β,9α,13α)-4-hydroxy-3,7-dimethoxy-17-methylmorphinan-6-one; (9α,13α)-3,7-dimethoxy-17-methyl-6-oxo-7,8-didehydromorphinan-4-yl propionate; (9α,13α)-3,4,7-trimethoxy-17-methyl-7,8-didehydromorphinan-6-one; (9α,13α)-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one oxime; (9α,13α)-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-4,6-diol; (9α,13α)-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one N-oxide; (9α,13α)-6-amino-3,7-dimethoxy-17-methylmorphinan-4-ol; 4-{[(9α,13α)-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-yl]-oxy}-4-oxobutanoic acid; (9α,13α)-3,7-dimethoxy-17-methyl-4-(propionyloxy)-7,8-didehydromorphinan-6-yl propionate; (9α,13α)-17-benzyl-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-17-iium-6-one bromide; (9α,13α)-17-ethyl-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-17-iium-4,6-diol bromide; (9α,13α)-17-ethyl-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-17-iium-6-one bromide; (9α,13α)-4-(benzoyloxy)-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-yl benzoate; (9α,13α)-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-yl

benzoate; (9 $\alpha$ ,13 $\alpha$ )-6-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-4-yl benzoate.

An advantageous aspect of the invention relates to the use of sinomenine in obtaining pharmaceutical compositions for use in the treatment of cognitive deficiencies associated  
5 with cerebral ageing and with neurodegenerative diseases.

Another especially interesting aspect of the invention relates to the use, in obtaining pharmaceutical compositions for use in the treatment of cognitive deficiencies associated with cerebral ageing and with neurodegenerative diseases, of compounds of formula (Ia) and, more especially, of (9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one hydrazone; of (7 $\alpha$ ,9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methylmorphinan-6-one; of (7 $\beta$ ,9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methylmorphinan-6-one; of (9 $\alpha$ ,13 $\alpha$ )-3,7-dimethoxy-17-methyl-6-oxo-7,8-didehydromorphinan-4-yl propionate; of (9 $\alpha$ ,13 $\alpha$ )-3,4,7-trimethoxy-17-methyl-7,8-didehydromorphinan-6-one; of (9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one oxime; of (9 $\alpha$ ,13 $\alpha$ )-15 3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-4,6-diol; of (9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one N-oxide; of (9 $\alpha$ ,13 $\alpha$ )-6-amino-3,7-dimethoxy-17-methylmorphinan-4-ol; of 4-{{(9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-yl]oxy}-4-oxobutanoic acid; of (9 $\alpha$ ,13 $\alpha$ )-3,7-dimethoxy-17-methyl-4-(propionyloxy)-7,8-didehydromorphinan-6-yl propionate; of (9 $\alpha$ ,13 $\alpha$ )-20 17-benzyl-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-17-iium-6-one bromide; of (9 $\alpha$ ,13 $\alpha$ )-17-ethyl-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-17-iium-4,6-diol bromide; of (9 $\alpha$ ,13 $\alpha$ )-17-ethyl-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-17-iium-6-one bromide; of (9 $\alpha$ ,13 $\alpha$ )-4-(benzoyloxy)-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-yl benzoate; of (9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-25 17-methyl-7,8-didehydromorphinan-6-yl benzoate; of (9 $\alpha$ ,13 $\alpha$ )-6-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-4-yl benzoate.

The invention relates also to pharmaceutical compositions comprising sinomenine or a compound thereof, in combination with one or more pharmaceutically acceptable


excipients, for use in the treatment of cognitive deficiencies associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias.

5 Among the pharmaceutical compositions according to the invention, there may be mentioned more especially those that are suitable for oral, parenteral (intravenous or subcutaneous) or nasal administration, tablets or dragées, sublingual tablets, gelatin capsules, lozenges, suppositories, creams, ointments, dermal gels, injectable preparations, drinkable suspensions etc..

10 The useful dosage can be varied according to the nature and severity of the disorder, the administration route and also the age and weight of the patient. The dosage varies from 0.01 mg to 1 g per day in one or more administrations.

The following Examples illustrate the invention but do not limit it in any way.

**EXAMPLE 1 : (9 $\alpha$ ,13 $\alpha$ )-1-Chloro-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one**



15

To a solution of 100 mg of the compound of formula (II) in 5 ml of CHCl<sub>3</sub> there are added 3 drops of SO<sub>2</sub>Cl<sub>2</sub>. The reaction mixture is stirred at ambient temperature for 4 hours and the pH is adjusted to 7-8 with NaHCO<sub>3</sub> solution; extraction with CHCl<sub>3</sub> is then carried out. The organic phase is evaporated under reduced pressure and the residue obtained is

chromatographed on silica gel using an eluant CHCl<sub>3</sub>-MeOH (9 : 1) to yield the title compound in the form of a yellowish solid.

*Melting point* : 126-128°C.

5      **EXAMPLE 2 : (9α,13α)-1-Chloro-3,7-dimethoxy-17-methyl-6-oxo-7,8-didehydro-**  
**morphinan-4-yl propionate**

To a solution of 500 mg of the compound obtained in Example 1 and 100 mg of DMAP in 15 ml of pyridine there are slowly added 2 ml of propionic anhydride, and the reaction mixture is stirred at ambient temperature for 3 hours. The reaction mixture is then evaporated and the residue obtained is dissolved in a small volume of water. The solution obtained is adjusted to pH = 8-9 with NaHCO<sub>3</sub> solution and is then extracted with CHCl<sub>3</sub>. The organic phase is washed 3 times with water, dried over sodium sulphate and evaporated. The residue obtained is chromatographed on silica gel using an eluant CHCl<sub>3</sub>-MeOH (20 : 1) to yield the title compound in the form of a colourless oil.

10     **EXAMPLE 3 : (6β,7β,9α,13α)-1-Chloro-3,7-dimethoxy-17-methylmorphinan-4,6-**  
15     **diol**

A mixture of 720 mg of compound of Example 1 and 100 mg of PtO<sub>2</sub> in 50 ml of absolute ethanol is stirred at room temperature under H<sub>2</sub> atmosphere for 12 hours. The PtO<sub>2</sub> is removed by filtration and the ethanol is evaporated in vacuum to give a syrupy residue. This residue is washed with hot absolute ethanol (10 ml) to give a powdery solid which is collected by filtration and crystallized in CHCl<sub>3</sub>/C<sub>2</sub>H<sub>5</sub>OH to give the title compound in the form of white crystals.

*Melting point* : 210-212°C.

20     **EXAMPLE 4 : (9α,13α)-1-Chloro-3,7-dimethoxy-17-methyl-7,8-didehydro-**  
**morphinan-4,6-diol**

25     To a solution of 500 mg of the compound obtained in Example 1 in 15 ml of methanol there are added 500 mg of NaBH<sub>4</sub>, and the reaction mixture is stirred for 1.5 hours. The

methanol is then evaporated off and the residue obtained is extracted with CHCl<sub>3</sub>. The organic phase is dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure. The title compound is obtained in the form of white crystals, by recrystallisation from Et<sub>2</sub>O.

*Melting point : 118-120°C.*

5      **EXAMPLE 5 : (9α,13α)-1-Chloro-3,7-dimethoxy-17-methyl-4-(propionyloxy)-7,8-didehydromorphinan-6-yl propionate**

The title compound is obtained using the procedure described for Example 2, starting from the compound obtained in Example 4.

Oil.

10     **EXAMPLE 6 : (6β,7β,9α,13α)-1-Chloro-3,7-dimethoxy-17-methyl-4-(propionyloxy)-morphinan-6-yl propionate**

The title compound is obtained using the procedure described for Example 2, starting from the compound obtained in Example 3.

Oil.

15     **EXAMPLE 7 : (9α,13α)-1-Chloro-3,4,7-triméthoxy-17-methyl-7,8-didehydro-morphinan-6-one**

A solution of 400 mg of the compound of Example 1 in 10 ml of methanol is treated with an excess of a freshly made preparation of diazomethane in ether, and the reaction mixture is stirred at ambient temperature for 12 hours. The excess of diazomethane is then broken down using glacial acetic acid, and the solvents are evaporated off under reduced pressure. The residue obtained is adjusted to pH = 8-9 using saturated NaHCO<sub>3</sub> solution and is then extracted with CHCl<sub>3</sub>. The organic phase is dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated *in vacuo*, and the residue obtained is chromatographed on silica gel (eluant CHCl<sub>3</sub>-MeOH) to yield the title product in the form of an oil.

**EXAMPLE 8 : (9 $\alpha$ ,13 $\alpha$ )-1-Chloro-3,4,7-trimethoxy-17-méthyl-7,8-didehydro-morphinan-6-ol**

The title compound is obtained using the procedure described for Example 4, starting from the compound obtained in Example 7.

5 Colourless crystals.

*Melting point* : 163-165°C.

**EXAMPLE 9 : (9 $\alpha$ ,13 $\alpha$ )-1-Chloro-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one oxime**

To a solution of 360 mg of the compound obtained in Example 1 in ethanol there are added 10 200 mg of NH<sub>2</sub>OH . HCl and 300 mg of sodium acetate. The reaction mixture is stirred for 4 hours; it is then filtered and evaporated under reduced pressure. The residue obtained is made alkaline using NaHCO<sub>3</sub> solution and extracted with CHCl<sub>3</sub>. The organic phase is dried over Na<sub>2</sub>SO<sub>4</sub> and then evaporated under reduced pressure, and the title compound is obtained in the form of needles, by recrystallisation from EtOH.

15 *Melting point* : 167-169°C.

**EXAMPLE 10 : (9 $\alpha$ ,13 $\alpha$ )-1-Chloro-6-ethoxy-4-hydroxy-3-methoxy-17-methyl-5,6-didehydromorphinan-7-one**

To a solution of 1.3 g of the compound obtained in Example 1 in 100 ml of CHCl<sub>3</sub> and 20 10 ml of absolute alcohol there is added SO<sub>2</sub>Cl<sub>2</sub> at 10°C, and the reaction mixture is stirred for 8 hours. The solvent is then evaporated off under reduced pressure, and the residue is neutralised using NaHCO<sub>3</sub> and then extracted with CHCl<sub>3</sub>. The organic phase is dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure, and the title compound is obtained in the form of yellowish crystals, by recrystallisation from CH<sub>3</sub>CN.

*Melting point* : 190-192°C.

**EXAMPLE 11 : (9 $\alpha$ ,13 $\alpha$ )-1-Chloro-4-hydroxy-3,7-dimethoxy-17-méthyl-7,8-didehydromorphinan-6-one hydrazone**

A solution of 600 mg of the compound obtained in Example 1 in 10 ml of 85 % hydrazine is stirred at 90°C for 8 hours. After cooling, the reaction mixture is filtered and the solid obtained is washed with water and recrystallised from EtOH to yield the title compound in the form of yellowish crystals.

*Melting point : 235-237°C.*

**EXAMPLE 12 : (9 $\alpha$ ,13 $\alpha$ )-1-Bromo-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one**

10 A solution of 6.6 g of the compound obtained in Example 1 in 150 ml of CHCl<sub>3</sub> is cooled to 0°C, and bromine dried over concentrated sulphuric acid is added dropwise, with stirring, whilst maintaining the reaction mixture at 5°C. The reaction is continued for a few minutes and then neutralisation is carried out using NaHCO<sub>3</sub>. The organic phase is separated off, dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure, and the residue obtained is recrystallised from EtOH to yield the title compound in the form of brown crystals.

15

*Melting point : 163-165°C.*

**EXAMPLE 13 : (9 $\alpha$ ,13 $\alpha$ )-1-Bromo-3,7-dimethoxy-17-methyl-7,8-didehydro-morphinan-4,6-diol**

20 The title compound is obtained using the procedure described for Example 4, starting from the compound obtained in Example 12 and replacing NaBH<sub>4</sub> by KBH<sub>4</sub>.

Solid.

*Melting point : 144-146°C.*

**EXAMPLE 14 : (9 $\alpha$ ,13 $\alpha$ )-1-Bromo-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one hydrazone**

The title compound is obtained using the procedure described for Example 11, starting from the compound obtained in Example 12.

5 Solid.

*Melting point* : 208-210°C.

**EXAMPLE 15 : (9 $\alpha$ ,13 $\alpha$ )-1-Bromo-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one oxime**

10 The title compound is obtained using the procedure described for Example 9, starting from the compound obtained in Example 12.

Solid.

*Melting point* : 180-182°C.

**EXAMPLE 16 : (9 $\alpha$ ,13 $\alpha$ )-1-Bromo-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one N-oxide**

15 A mixture of compound of Example 12 (820 mg) in H<sub>2</sub>O<sub>2</sub> (10 ml) is stirred at room temperature for 24 hours and then extracted with CHCl<sub>3</sub> three times (30 ml X 3). The combined extracts are dried overnight with anhydrous Na<sub>2</sub>SO<sub>4</sub> and the solvent is removed by evaporation to give a residue to which are added 30 ml of cold water. The powdery solid is collected by filtration, washed with cold water until the water being colorless, and  
20 crystallized in ethanol to give the title compound as a solid.

*Melting point* : 170-172°C.

**EXAMPLE 17 : (9 $\alpha$ ,13 $\alpha$ )-1-Chloro-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one N-oxide**

25 A mixture of compound of Example 1 (720 mg) in H<sub>2</sub>O<sub>2</sub> (10 ml) is stirred at room temperature for 24 hours and then extracted three times (25 ml X 3). The combined

extracts are dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and the solvent is removed by evaporation. 30 ml of cold water are added to the residue obtained and the resulting powdery white solid is collected by filtration and crystallized in ethanol to give the title compound as a solid.

*Melting point* : 170-172°C.

5      **EXAMPLE 18 : (9α,13α)-1-Bromo-3,7-dimethoxy-17-methylmorphinan-4,6-diol**

The title compound is obtained using the procedure described for Example 3, starting from the compound obtained in Example 12.

*Melting point* : 160-162°C.

10     **EXAMPLE 19 : (9α,13α)-1-Chloro-6-ethoxy-3-methoxy-17-methyl-5,6-didehydro-**  
**morphinan-4,7-diol**

The title compound is obtained using the procedure described for Example 4, starting from the compound obtained in Example 10 and replacing NaBH<sub>4</sub> by KBH<sub>4</sub>.

Solid.

*Melting point* : 168-170°C.

15     **EXAMPLE 20 : (9α,13α)-1-Chloro-6-ethoxy-4-hydroxy-3-methoxy-17-methyl-5,6-**  
**didehydromorphinan-7-one oxime**

The title compound is obtained using the procedure described for Example 9, starting from the compound obtained in Example 10.

Solid.


20     *Melting point* : 216-218°C.

**EXAMPLE 21 : (9α,13α)-17-Benzyl-1-bromo-4-hydroxy-3,7-dimethoxy-17-methyl-**  
**7,8-didehydromorphinan-17-iun-6-one bromide**

The title compound is obtained from compound of example 12 subjected to the action of benzylbromide.

*Melting point : 190-192°C.*

**EXAMPLE 22 :**



The title compound is obtained after treatment of compound of Example 1 in basic medium.

5      *Melting point : 204-206°C.*

**EXAMPLE 23 : (9α,13α)-1-Chloro-4-hydroxy-6-isopropoxy-3-methoxy-17-methyl-5,6-didehydromorphinan-7-one**

The title compound is obtained using the procedure described in Example 10 replacing absolute alcohol with isopropylic alcohol.

10     *Melting point : 216-218°C.*

**EXAMPLE 24 : (9α,13α)-1-Chloro-3,7-dimethoxy-17-methyl-6-oxo-7,8-didehydromorphinan-4-yl chloroacetate**

The title compound is obtained using the procedure described in Example 2 replacing propionic anhydrid with chloroacetic anhydrid.

15     *Melting point : 223-225°C.*

## PHARMACOLOGICAL STUDY OF COMPOUNDS OF THE INVENTION

**EXAMPLE A : Acute toxicity study**

Acute toxicity was evaluated after oral administration to groups each comprising 8 mice ( $26 \pm 2$  grams). The animals were observed at regular intervals during the course of the

first day, and daily for the two weeks following treatment. The LD<sub>50</sub> (dose that causes the death of 50 % of the animals) was evaluated and demonstrated the low toxicity of the compounds of the invention.

**EXAMPLE B : Morris water maze test in the mouse**

5      The anti-amnesic effects of the compounds of the present invention have been evaluated using the Morris water maze test (Morris *et al.*, Nature, 1986, 319, 774-776) in the mouse and scopolamine as amnesic agent. Kumming strain mice (18-24g, Shanghai Experimental Animal Centre) of either sex were used. Mice were placed on the water maze (80x50x20 cm) and trained to find the platform. Following the period of one day's  
10     habituation, each mouse received 3 daily training sessions for seven days. Mice were trained to a criterion of finding the platform within 20 seconds and with <2 errors of entering a dead-end. Once a mouse met the criterion, training was reduced to one daily session until all mice met the criterion. Trained mice were randomly assigned to sub-groups. Compounds under study were dissolved in distilled water and administered by the  
15     oral route 40 minutes before behavioural testing. Scopolamine (5 mg/kg, i.p.) was injected 30 minutes before the test. The number of errors and the time for reaching the platform were recorded. Data were expressed as means +/- s.e.m. Statistical analysis was performed using ANOVA followed by Duncan's multiple-range test.

Results demonstrate that compounds of the present invention were capable of  
20     counteracting in a dose-dependent manner (from 20 to 100 mg/kg) scopolamine-induced memory impairments in the Morris water maze test in the mouse, indicating that such compounds possess anti-amnesic properties. As example, compound of Example 4 gave the following results :

- { Scopolamine : 0                          ⇒ Latency to find the platform = 15 s  
Example 4 : 0
- { Scopolamine : 3 mg/kg                          ⇒ Latency to find the platform = 55 s  
Example 4 : 0
- 5 { Scopolamine : 3 mg/kg                          ⇒ Latency to find the platform = 35 s  
Example 4 : 20 mg/kg
- { Scopolamine : 3 mg/kg                          ⇒ Latency to find the platform = 25 s  
Example 4 : 30 mg/kg

**EXAMPLE C : Social recognition in the Wistar rat**

- 10 Initially described in 1982 by THOR and HOLLOWAY (J. Comp. Physiol., 1982, 96, 1000-1006), the social recognition test has subsequently been proposed by various authors (DANTZER *et al.*, Psychopharmacology, 1987, 91, 363-368 ; PERIO *et al.*, Psychopharmacology, 1989, 97, 262-268) for studying the mnemocognitive effects of new compounds. The test is based on the natural expression of the olfactory memory of the rat and its natural tendency to forget, and allows evaluation of memorisation, by recognition of a young congeneric animal, by an adult rat. A young rat (21 days), taken at random, is placed for 5 minutes in the cage housing an adult rat. With the aid of a video device, the experimenter observes the social recognition behaviour of the adult rat and measures its overall duration. The young rat is then removed from the adult rat's cage and is placed in its own cage until the second introduction. The adult rat is given the compound under test and, after 2 hours, is again brought into the presence (5 minutes) of the young rat. The social recognition behaviour is then observed again and its duration measured. The assessment criterion is the difference ( $T_2-T_1$ ), expressed in seconds, between the "recognition" times of the 2 encounters.
- 15
- 20
- 25 The results obtained show a difference ( $T_2-T_1$ ) ranging from (-10) s to (-36) s for doses ranging from 3 to 30 mg/kg, which shows that the compounds of the invention very greatly enhance memorisation. As example, compound of Example 13 at a dose of 20 mg/kg showed a difference ( $T_2-T_1$ ) of - 36 s, and compound of Example 5 a ( $T_2-T_1$ ) of - 31 s.

**EXAMPLE D : Object recognition in the Wistar rat**

The object recognition test in the Wistar rat was initially developed by ENNACEUR and DELACOUR (Behav. Brain Res., 1988, 31, 47-59). The test is based on the spontaneous exploratory activity of the animal and has the characteristics of episodic memory in humans. This memory test is sensitive to ageing (SCALI *et al.*, Eur. J. Pharmacol., 1997, 325, 173-180) and to cholinergic dysfunctions (BARTOLINI *et al.*, Pharm. Biochem. Behav. 1996, 53(2), 277-283) and is based on the differences in the exploration of 2 objects of fairly similar shape – one familiar, the other new. Prior to the test, the animals are habituated to the environment (an enclosure without an object). In the course of a first session, the rats are placed (3 minutes) in the enclosure, in which there are 2 identical objects. The duration of exploration is measured for each object. In the course of the second session (3 minutes), 24 hours later, 1 of the 2 objects is replaced by a new object. The duration of exploration is measured for each object. The assessment criterion is the difference, Delta, expressed in seconds, between the exploration times for the new object and for the familiar object in the course of the second session. The control animals, previously treated with the carrier by the IP route 30 minutes before each session, explore the familiar object and the new object in an identical manner, which indicates that the object introduced earlier has been forgotten. Animals treated with a compound that facilitates mnemocognition preferentially explore the new object, which indicates that the object introduced earlier has been remembered.

The results obtained show a difference, Delta, ranging from 5 to 11 s, for doses ranging from 0.3 to 10 mg/kg, which shows that the compounds of the invention greatly enhance memorisation. As example, compound of Example 4 showed a Delta of 10 s at a dose of 3 mg/kg.

**EXAMPLE E : NANO<sub>2</sub> induced anoxia in mice**

The neuroprotective effects of the compounds of the present invention have been evaluated in mice. Kunming strain mice of either sex were supplied by Shanghai Experimental Animal Center, Chinese Academy of Sciences (Grade clear, Certificate N°005). Mice

weighing 22-28 g were kept in a 12 hours-light-dark cycle and given food and water *ad libitum*. Compounds under study were dissolved in a 5 % polysorbate-80 solution and orally administered (50 mg/kg) 60 minutes prior to the administration of NaNO<sub>2</sub> at a dose of 225 mg/kg *ip*. Lethality was observed and the prolongation of survival was recorded.

5 The results obtained indicate that the compounds of the present invention were able to increase the survival of mice after an *ip* administration of NaNO<sub>2</sub>. These results demonstrate that the compounds of the present invention possess patent anti-anoxic and neuroprotective effects in the mouse. As example, compound of Example 5 shows a prolongation of survival of 31 % at 70 mg/kg *p.o.*.


10 **EXAMPLE F : Pharmaceutical composition**

Formula for the preparation of 1000 tablets each containing 10 mg of active ingredient:

(9 $\alpha$ ,13 $\alpha$ )-1-Bromo-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-4,6-diol .....	10 g
hydroxypropylcellulose .....	2 g
15 wheat starch .....	10 g
lactose .....	100 g
magnesium stearate.....	3 g
talc .....	3 g

## CLAIMS

## 1. Compounds of formula (I) :



wherein

- 5     •  $R_1$  represents an alkyl group,
- $R_2$  represents a hydrogen atom or an alkylcarbonyl group, an haloalkylcarbonyl group or an arylcarbonyl group,
- $Y$  represents a group  $\begin{array}{c} >NR_7 \\ | \end{array}$ ,  $\begin{array}{c} + \\ | \\ >N-O^- \\ | \\ R_7 \end{array}$  or  $\begin{array}{c} + \\ | \\ >N-R_7 \\ | \\ R'_7 \end{array} Z^-$

10     wherein  $R_7$  and  $R'_7$ , identical or different, each represent an alkyl group, and  $Z^-$  represents a halogen anion,

- $R_3$  represents a hydroxy or alkoxy group,
- $R_4$  and  $R'_4$  each represent a hydrogen atom or together form an additional bond, or  $R_3$  and  $R_4$  together form an oxo or  $=N-OR_8$  group (wherein  $R_8$  represents a hydrogen atom or an alkyl group),
- 15     •  $R_6$  represents a hydroxy, alkylcarbonyloxy (wherein the alkyl moiety can be substituted by a hydroxy, alkoxy, carboxy or alkyloxycarbonyl group) or alkoxy group,
- $R_5$  and  $R'_5$  each represent a hydrogen atom or together form an additional bond,

or R<sub>5</sub> and R<sub>6</sub> together form an oxo, =N-OR<sub>9</sub> or =N-NR<sub>10</sub>R<sub>11</sub> group (wherein R<sub>9</sub>, R<sub>10</sub>, and R<sub>11</sub>, which may be the same or different, each represent a hydrogen atom or an alkyl group),

- and X represents a halogen atom,

5 with the proviso that the compound of formula (I) cannot represent 1-bromo-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one,

it being understood that

- "alkyl" means an alkyl group containing 1 to 6 carbon atoms which may be linear or branched,
- "alkoxy" means an alkyloxy group containing 1 to 6 carbon atoms which may be linear or branched,

to their enantiomers and diastereoisomers, and to addition salts thereof with a pharmaceutically acceptable acid or base.

2. Compounds of formula (I) according to claim 1, wherein R<sub>1</sub> represents a methyl

15 group, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

3. Compounds of formula (I) according to claim 1, wherein R<sub>2</sub> represents a hydrogen

atom, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

20 4. Compounds of formula (I) according to claim 1, wherein R<sub>2</sub> represents an


alkylcarbonyl group, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

5. Compounds of formula (I) according to claim 1, wherein R<sub>2</sub> represents an

25 ethylcarbonyl group, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.


6. Compounds of formula (I) according to claim 1, wherein Y represents a group NR<sub>7</sub>, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
- 5      7. Compounds of formula (I) according to claim 1, wherein Y represents a group  $\begin{array}{c} + \\ \text{N} \\ \diagup \quad \diagdown \\ \text{R}_7 \quad \text{O}^- \end{array}$ , their enantiomers and diastereoisomers, an addition salts thereof with a pharmaceutically acceptable acid or base.
8. Compounds of formula (I) according to claim 1, wherein X represents a chlorine atom, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
- 10     9. Compounds of formula (I) according to claim 1, wherein X represents a bromine atom, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
- 15     10. Compounds of formula (I) according to claim 1, wherein R<sub>3</sub> represents an alkoxy group, and R<sub>4</sub> and R'<sub>4</sub> together form an additional bond, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
11. Compounds of formula (I) according to claim 1, wherein R<sub>5</sub> represents a hydrogen atom, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
- 20     12. Compounds of formula (I) according to claim 1, wherein R<sub>6</sub> represents an OH group, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

13. Compounds of formula (I) according to claim 1, wherein R<sub>6</sub> represents an alkylcarbonyloxy group, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
14. Compounds of formula (I) according to claim 1, wherein R<sub>5</sub> and R<sub>6</sub> together form an oxo group, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.  
5
15. Compounds of formula (I) according to claim 1, wherein R<sub>5</sub> and R<sub>6</sub> together form a —N—OH group, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.
16. Compound of formula (I) according to claim 1, which is (9α,13α)-1-chloro-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-4,6-diol.  
10
17. Compound of formula (I) according to claim 1, which is (9α,13α)-1-chloro-3,7-dimethoxy-17-methyl-4-(propionyloxy)-7,8-didehydromorphinan-6-yl propionate.
18. Compound of formula (I) according to claim 1, which is (9α,13α)-1-Bromo-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-4,6-diol.  
15
19. Compounds of formula (I) according to claim 1, which is (9α,13α)-1-Bromo-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one oxime.
20. Compounds of formula (I) according to claim 1, which is (9α,13α)-1-Bromo-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one N-oxide.
21. Compounds of formula (I) according to claim 1, which is (9α,13α)-1-Chloro-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one N-oxide.  
20
22. Compounds of formula (I) according to claim 1, having the configuration shown by formula (I') :




and addition salts thereof with a pharmaceutically acceptable acid or base.

- 23.** Process for the preparation of compounds of formula (I) according to claim 1, characterised in that there is used as starting material the compound of formula (II) :




5

obtained by extraction starting from the stem of *Sinomenium acutum* according to Figure 1 below :



**Figure 1 : Extraction of the compound of formula (II)**

which is subjected to the action of a halogenating agent such as  $\text{SO}_2\text{Cl}_2$  or  $\text{Br}_2$  to obtain the compound of formula (I/a), a particular case of the compounds of formula (I):




wherein X is as defined for formula (I), which compound of formula (I/a) is subjected to conventional chemical reactions to obtain the totality of the compounds of formula (I), which may be purified according to a conventional separation technique, are converted, if desired, into their addition salts with a pharmaceutically acceptable acid or base and are separated, where appropriate, into their isomers according to a conventional separation technique.

- 10      24. Pharmaceutical compositions comprising at least one compound of formula (I) according to any one of claims 1 to 22 or an addition salt thereof with a pharmaceutically acceptable acid or base, in combination with one or more pharmaceutically acceptable excipients.
- 15      25. Pharmaceutical compositions according to claim 24 for use in the manufacture of medicaments for the treatment of deficiencies of memory associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias.
- 20      26. Use of sinomenine and/or sinomenine compounds in obtaining pharmaceutical compositions intended for the treatment of deficiencies of memory associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease,

Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias.

- 5           **27.** Use, according to claim 26, of sinomenine in obtaining pharmaceutical compositions intended for the treatment of deficiencies of memory associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias.
- 10          **28.** Use, according to claim 26, of sinomenine compounds in obtaining pharmaceutical compositions intended for the treatment of deficiencies of memory associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias.
- 29.** Use, according to claim 26, of sinomenine compounds of formula (Ia) :



15          wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R'<sub>4</sub>, R<sub>5</sub>, R'<sub>5</sub>, R<sub>6</sub> and Y are as defined in claim 1, in obtaining pharmaceutical compositions intended for the treatment of deficiencies of memory associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias.

- 20          **30.** Use, according to claim 26, of sinomenine compounds that are: (9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one hydrazone; (7 $\alpha$ ,9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methylmorphinan-6-one; (7 $\beta$ ,9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-di-

methoxy-17-methylmorphinan-6-one; (9 $\alpha$ ,13 $\alpha$ )-3,7-dimethoxy-17-methyl-6-oxo-7,8-didehydromorphinan-4-yl propionate; (9 $\alpha$ ,13 $\alpha$ )-3,4,7-trimethoxy-17-methyl-7,8-didehydromorphinan-6-one; (9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one oxime; (9 $\alpha$ ,13 $\alpha$ )-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-4,6-diol; (9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-one N-oxide; (9 $\alpha$ ,13 $\alpha$ )-6-amino-3,7-dimethoxy-17-methylmorphinan-4-ol; 4-{[(9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-yl]-oxy}-4-oxobutanoic acid; (9 $\alpha$ ,13 $\alpha$ )-3,7-dimethoxy-17-methyl-4-(propionyloxy)-7,8-didehydromorphinan-6-yl propionate (9 $\alpha$ ,13 $\alpha$ )-17-benzyl-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-17-iun-6-one bromide; (9 $\alpha$ ,13 $\alpha$ )-17-ethyl-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-17-iun-4,6-diol bromide; (9 $\alpha$ ,13 $\alpha$ )-17-ethyl-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-17-iun-6-one bromide; (9 $\alpha$ ,13 $\alpha$ )-4-(benzoyloxy)-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-yl benzoate; (9 $\alpha$ ,13 $\alpha$ )-4-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-6-yl benzoate; (9 $\alpha$ ,13 $\alpha$ )-6-hydroxy-3,7-dimethoxy-17-methyl-7,8-didehydromorphinan-4-yl benzoate, in obtaining pharmaceutical compositions intended for the treatment of deficiencies of memory associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias.

31. Pharmaceutical compositions comprising sinomenine or a sinomenine compound, in combination with one or more pharmaceutically acceptable excipients, for use in the treatment of deficiencies of memory associated with cerebral ageing and with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Pick's disease, Korsakoff's disease, and frontal lobe and subcortical dementias.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/14841

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 C07D221/28 C07D489/00 A61K31/485

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, EMBASE

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	IIJIMA I ET AL: JOURNAL OF MEDICINAL CHEMISTRY, vol. 21, no. 12, 1978, pages 1320-1322, XP002273127 Scheme I	1-3,7, 9-11,14
A	WHITE, JAMES D. ET AL: "Biomimetic total synthesis of (-)-codeine" TETRAHEDRON, 39(14), 2393-7 CODEN: TETRAB; ISSN: 0040-4020, 1983, XP002273128 See compounds 9-12	1
A	US 4 912 114 A (REVESZ LASZLO) 27 March 1990 (1990-03-27) column 1, line 10 - column 1, line 62 column 20, line 4 - column 20, line 21	1-31

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the International filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the International search

11 March 2004

Date of mailing of the International search report

26/03/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Usually, A

**INTERNATIONAL SEARCH REPORT**

International Application No

PCT/EP 03/14841

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 661 283 A (TORAY INDUSTRIES) 5 July 1995 (1995-07-05) page 3, line 6 – page 4, line 37 -----	1-31

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP 03/14841

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 4912114	A 27-03-1990	NONE		
EP 0661283	A 05-07-1995	CA	2144770 A1	02-02-1995
		DE	69414085 D1	26-11-1998
		DE	69414085 T2	18-03-1999
		EP	0661283 A1	05-07-1995
		WO	9503307 A1	02-02-1995
		TW	401400 B	11-08-2000
		US	6147084 A	14-11-2000
		US	5972953 A	26-10-1999